MoonLake Immunotherapeutics
MoonLake Immunotherapeutics
Join ActionIf you are a MoonLake investor who suffered a loss and would like to learn more, you can provide your information below:
Did You Lose Money in MoonLake Immunotherapeutics (NASDAQ: MLTX) Stock?
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against MoonLake Immunotherapeutics (“MoonLake” or the “Company”) for alleged violations of federal securities laws. The firm reminds investors that they have until December 15, 2025 to seek appointment as lead plaintiff in the class action filed against the Company.
The complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose: (1) that SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL-17A and IL-17F); (2) that SLK’s distinct Nanobody structure would not confer a superior clinical benefit over the traditional monoclonal structure of BIMZELX; (3) SLK’s distinct Nanobody structure supposed increased tissue penetration would not translate to clinical efficacy; and (4) based on the foregoing, Defendants lacked a reasonable basis for their positive statements regarding SLK’s purported superiority to monoclonal antibodies.
If you purchased MLTX securities between March 10, 2024 and September 29, 2025 , you may be eligible to recover your losses.
Lead Plaintiff Deadline: December 15, 2025
📞 Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310)
💻 Or submit your information below to learn about your rights.